Investor Presentation - Diversifying, focusing on growth
Released
Released
Announcement PDF
© 2026 Doctor Care Anywhere
1
Doctor Care Anywhere Group PLC (ASX: DOC) (“Doctor Care Anywhere”, “DCA” or
the “Company”) ARBN: 645 163 873
Investor
Presentation
Diversifying the business,
focusing on growth
9 November 2026
© 2026 Doctor Care Anywhere
2
Important notice and disclaimer
This presentation is for information purposes only and it is not financial product or investment advice.
The presentation is not intended to be comprehensive or provide all information required by investors to
make an informed decision on any investment in Doctor Care Anywhere Group PLC, incorporated in
England and Wales with company number 08915336 and registered as a foreign company in Australia
ARBN 645 163 873 (the "Company"). In preparing this presentation, the Company did not take into
account the investment objectives, financial situation or particular needs of any particular reader.
Readers should obtain their own investment, legal and tax advice before taking any action on any
information dealt with in the presentation.
Whilst this presentation is based on information from sources which are considered reliable, no
representation or warranty, express or implied, is made or given by or on behalf of the Company, any of
its directors, or any other person about the accuracy, completeness or fairness of the information or
opinions contained in this presentation. No responsibility or liability is accepted by any of them for that
information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for
any communication written or otherwise, contained or referred to in this presentation.
Neither the Company nor any of its directors, officers, employees, advisors, associated persons or
subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a
result of relying upon any statement in the presentation or any document supplied with this
presentation, or by any future communications in connection with those documents and all of those
losses and damages are expressly disclaimed.
All amounts are in British pounds (£ or GBP) unless otherwise indicated. A number of figures, amounts,
percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of
rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this
presentation.
Figures for the three months to 30 September 2026 are unaudited management figures, as reported in
the Company's Q3 2026 trading update of 30 October 2026. This presentation contains no new financial
information.
Investors should also be aware that certain financial data included in this presentation including EBITDA
and measures described as "pro forma", are "non-IFRS financial information" under ASIC Regulatory
Guide 230 (Disclosing non-IFRS financial information). The non-IFRS financial information financial
measures do not have a standardised meaning prescribed by Australian International Financial Reporting
Standards (AIFRS) and, therefore, may not be comparable to similarly titled measures presented by other
companies, nor should they be construed as an alternative to other financial measures determined in
accordance with AIFRS. Investors are cautioned, therefore, not to place undue reliance on any non-IFRS
financial measures included in this presentation.
This presentation may contain forward-looking statements regarding the Company's intent, belief or
current expectations with respect to its business and operations, market conditions, results of operations
and financial conditions. Words such as 'will', 'may', 'expect', 'indicative', 'plan', 'intend', 'seek', 'would',
'should', 'risk', 'forecast' and similar expressions indicate forward-looking statements which reflect the
Company's current views with respect to future events and are subject to change and involve risks,
uncertainties and assumptions that could cause actual outcomes to differ materially from the outcomes
anticipated. Accordingly, readers should not place undue reliance on forward-looking statements.
Any opinions expressed reflect the Company's position at the date of this presentation and are subject to
change. Subject to applicable law, the Company assumes no obligation to update, review or revise any
information contained in this presentation, whether as a result of new information, future events or
otherwise. Past performance cannot be relied upon as a guide to future performance.
References to Doctor Care Anywhere in this presentation are to the Doctor Care Anywhere Group
including the Company and all subsidiaries, unless stated otherwise.
© 2026 Doctor Care Anywhere
3
INVESTMENT CASE
Why invest in DCA
A profitable UK virtual care platform at scale, broadening into growing self-pay and employer markets
PROFITABLE
£2.6m
H1 FY26 EBITDA, up 27%;
free cash flow £1.5m, more
than doubled
DIVERSIFYING
19%
of Q3 2026 revenue from
subscriptions, up from 8% a
year earlier
TAILWIND
2.4m
UK adults using GLP-1
medication, from 0.5m at
the end of 2024
FUNDED
£8.3m
cash at 30 September 2026,
with positive free cash flow
THE INVESTMENT THESIS
1
The platform is built
2
Performance is
strengthening
3
The tailwinds are
structural
4
Growth pathways
unlocked
5
Funded to deliver
Sources: H1 FY26 results, 3 September 2026; Q3 2026 trading update, 30 October 2026; The Health Foundation with Voy, February 2026
© 2026 Doctor Care Anywhere
4
INVESTMENT THESIS 1 OF 5
The platform is built: care 24/7, 365 days a year
Today: a trusted virtual GP platform at scale
350k+
consultations in H1
2026
74%
of consultations from
repeat patients
600+
clinical and
operational workforce
100%
of patients seen
within 24 hours
24/7
365 days a year
71
average Net Promoter
Score, 2025
CLINICAL BREADTH
GPs, advanced clinical practitioners, mental health practitioners and
physiotherapists
Four routes to market
Insurers
Paid per consultation; DCA carries no
underwriting risk
Employers
Subscriptions covering the whole workforce
Healthcare providers
Ramsay: self-pay GP with referral into its hospitals
Consumers
Subscriptions, led by weight management
Sources: FY2025 Annual Report, 26 March 2026; Strategy and Business Model Update, Tables 6.1 and 6.2; H1 FY26 results; Q3 2026 trading update
© 2026 Doctor Care Anywhere
5
INVESTMENT THESIS 1 OF 5
The evolving platform: The front door to whole-person care
Today, patients come to us when they’re unwell. Tomorrow, they stay with us to stay well.
Engagement at the core, this provides personalised nudges and content that turn single consultations into ongoing relationships,
driving engagement, retention and lifetime value.
Sources: Strategy and Business Model Update, Section 9.1; H1 FY26 presentation, 3 September 2026
Illustrative designs, subject to change
INVESTING IN A DIGITAL FRONT DOOR: THE MEMBER JOURNEY
One integrated healthcare experience
All your healthcare in one place, with one complete record your clinician uses to support
you.
Your healthcare concierge
AI-guided navigation learns about your life and points you to the right care at the right
time, backed by our clinicians.
Be curious about your health
Track goals, gain insights and use partner services on a platform that evolves as your
health needs change.
Better health outcomes and lasting behaviour change
Members act earlier and build healthier habits.
© 2026 Doctor Care Anywhere
6
INVESTMENT THESIS 2 OF 5
Performance is strengthening: revenue up 16% in Q3
The reset is working, led by new revenue
REVENUE
£11.3m
Up 16%: weight management £1.5m
CONSULTATIONS
174k
Up 2.6% on Q3 2025; 74% from repeat
patients
CONTRIBUTION MARGIN
43.5%
FY2025, from 38.3% in FY2024 (underlying)
Subscriptions, share of revenue
8%
11%
19%
Q3 2025 H1 2026 Q3 2026
Sources: Q3 2026 trading update, 30 October 2026; H1 FY26 results; Strategy and Business Model Update, Sections 1.3, 8.3. Three months to 30 September 2026, unaudited, against Q3 2025. Contribution margins underlying
How the reset worked
New leadership: a new Chief Executive from January 2025 set the
strategy and reset the cost base
Lower-cost clinical mix: mental health practitioners and
physiotherapists added; mix moved to 60:40 GP to ACP
Efficiency: variable appointment length, automation including an AI
scribe, and cost control
© 2026 Doctor Care Anywhere
7
INVESTMENT THESIS 3 OF 5
The tailwinds are structural: GLP-1, employer demand, NHS strain
Three tailwinds behind digital care, matched by the three growth levers
NHS capacity is stretched
7.3m
people on NHS waiting lists
340m+
NHS GP appointments a year
Employers want to offer more
34m
UK adults of working age
41%
of employees think their employer should
offer weight-management support
GLP-1 is now mainstream
2.4m
UK adults using GLP-1 medication, from
0.5m at the end of 2024
0.22m
of 3.4m eligible people reached by the
NHS rollout, over three years
£6.3bn UK telehealth market (DCA estimate); employer-funded and self-pay virtual GP growing about 8% a year
Sources: NHS England RTT waiting times; NHS Digital; ONS; Howden Employee Benefits, 2026; The Health Foundation with Voy, Feb 2026; NICE TA1026. Market size and segment growth are DCA estimates, the market size drawing on
Grand View Research: Strategy and Business Model Update, Section 1.4
© 2026 Doctor Care Anywhere
8
INVESTMENT THESIS 4 OF 5
Growth pathways unlocked: product, employer, hospital
Three levers, each already live, one for each tailwind
1 Weight management
Product and channel
TODAY
£1.5m revenue in Q3, 13% of Group; sold
direct and through Rippl and Live Like
Loyalty
WATCH
Weight-management revenue
2 Employer benefits
Whole of workforce health
TODAY
GP, mental health, physiotherapy, health
assessments and weight management
from one provider
WATCH
Subscription share of revenue
3 Hospital partner
Self-pay care with Ramsay
TODAY
Ramsay Health Care UK live from 20 July:
self-pay GP with referral into Ramsay
hospitals
WATCH
Consultations and revenue from Ramsay
All three levers grow subscription and self-pay revenue, and reduce reliance on a single insurer relationship
Sources: Q3 2026 trading update; H1 FY26 presentation; Strategy and Business Model Update, Sections 8.3, 9.1
© 2026 Doctor Care Anywhere
9
INVESTMENT THESIS 4 OF 5
Growth pathways unlocked: weight management at 13% of Group
Weight management: £1.5m in its first full quarter
£1.5m
Q3 revenue; 13% of Group
£0.85m
paid from cash, May 2026
2
partner platforms: Rippl,
Live Like Loyalty
Weight management, done properly
• 12 months of phased aftercare, with a personal health coach
• Integrated with DCA's virtual GP, mental health and physiotherapy
• GPhC and CQC regulated; NHS record checked for every prescribing decision
• Around 30% of applicants declined at screening
• Customers found through search, not paid acquisition
Sources: Q3 2026 trading update; H1 FY26 presentation; DCA and Medicspot programme materials, 2026
© 2026 Doctor Care Anywhere
10
INVESTMENT THESIS 4 OF 5
Growth pathways unlocked: one provider, whole of workforce
Virtual GP is the most used employer-provided health benefit
Whole of workforce health
• GP, mental health, physiotherapy, health assessments and weight
management on one platform
• Employer subscriptions cover the whole workforce, building
recurring revenue
• Rippl and Live Like Loyalty bring DCA Weight Management to their
members
Sources: H1 FY26 presentation (Mercer Marsh Benefits, The Changing Landscape of Virtual GP Services); Q3 2026 trading update
© 2026 Doctor Care Anywhere
11
INVESTMENT THESIS 4 OF 5
Growth pathways unlocked: self-pay care with Ramsay
Ramsay: self-pay GP care with referral into Ramsay's hospitals, live since 20 July 2026
The patient journey
• A Ramsay patient books a self-pay online GP appointment with DCA
• A DCA clinician assesses, treats and prescribes on DCA's own platform
• Where needed, the patient is referred on into Ramsay's hospitals and specialists
Why it matters
A new route to market: self-pay patients through a healthcare provider, alongside
insurers and employers
The model at work: a new service on the platform and clinicians DCA already has
Validation: Ramsay Health Care UK, part of ASX-listed Ramsay Health Care, chose
DCA's clinical service
Sources: H1 FY26 results, 17 August 2026; Q3 2026 trading update; Strategy and Business Model Update, short version, Section 9.2. Ramsay Health Care UK is part of Ramsay Health Care Limited (ASX: RHC)
© 2026 Doctor Care Anywhere
12
INVESTMENT THESIS 5 OF 5
Funded to deliver: free cash flow positive, investing in growth
Investing in growth, with clear priorities for the next 12 months
What to expect over the next 12 months
1. Broaden revenue through new products and channels.
2. Private hospitals and new partnerships showing in
consultations and revenue.
3. Keep free cash flow positive while investing in growth.
4. Medium-term targets reaffirmed: revenue of £76m within
three to five years, doubling from 2024, and a 15%
EBITDA margin.
5. Set out a clear path for the convertible notes ahead of
their December 2027 maturity.
Key dates Jan 2027 Q4 update · Feb 2027 FY2026 results ·
Dec 2027 notes mature
Sources: Strategy and Business Model Update, Sections 1.6, 2.3, 4.3, 5.3; H1 FY26 results; Q3 2026 trading update. Medium-term targets: Q1 2026 quarterly activity report, 23 April 2026, subject to the assumptions, risks and
qualifications described there. Dates indicative
CASH
£8.3m
at 30 September 2026
FREE CASH FLOW
£1.5m
in H1 FY26, more than
doubled
CONVERTIBLE NOTES
£10.6m
interest-free, due 31
December 2027
What to watch
Convertible notes: at maturity on 31 December 2027 the notes
convert, are repaid, or a mix of the two. Full conversion would be
about 38.7% of the enlarged share capital
Customer concentration: around 93% of FY2025 revenue came from
one insurer relationship. Subscriptions, 19% of Q3 revenue, are how
this falls
© 2026 Doctor Care Anywhere
13
APPENDIX
Financial metrics: half year to 30 June 2026
Statutory figures; H1 FY25 restated
H1 FY25 H1 FY26 What moved it
Consultations 349,900 354,900 Up 1.4%
Utilisation revenue £17.9m £18.2m Consultation volume
Subscription revenue £1.3m £2.2m Weight management: £0.9m in its first 54 days
Revenue £19.2m £20.4m Up 6.3%; the existing business up 1.7%
Contribution margin 41.0% 42.0% Labour hours and mix
EBITDA £2.1m £2.6m Up 27.1%
Free cash flow £0.7m £1.5m More than doubled
Sources: Strategy and Business Model Update, Sections 7A.1-7A.5, 8.3; H1 FY26 results. Free cash flow is non-IFRS: net cash from operating activities less purchases of property, plant and equipment and intangible assets
© 2026 Doctor Care Anywhere
14
Contact
Matthew Pearson, Investor Relations
investorenquiries@doctorcareanywhere.com
Doctor Care Anywhere Group PLC, 19-21 Great Portland Street, London W1W
8QB, United Kingdom
Company number 08915336 | ARBN 645 163 873 | ASX: DOC
This presentation has been authorised for release by the Board of Doctor Care
Anywhere Group PLC.
Share your feedback
Discover